Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22251108 | 0.81 | SMN1; SMN2 (0.50) | ALDH1A1MAPK1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL10412140 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL22029192 | 0.77 | NOS3 (0.38) | ALDH1A1POLB | |
| SCHEMBL25337588 | 0.77 | ALDH1A1 (0.36) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL11985859 | 0.75 | ALDH1A1 (0.39) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL31396216 | 0.75 | ALDH1A1 (0.39) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL3752930 | 0.75 | CYP3A4 (0.40) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL18260463 | 0.71 | TDP1 (0.44) | KDM4EKMT2AMEN1 | |
| SCHEMBL8545318 | 0.71 | ALDH1A1 (0.36) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL23797878 | 0.71 | ALDH1A1 (0.36) | ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | ALDH1A1 4462/4885MAPK1 1260/4885SMN1; SMN2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.